Chemical Regulation & Food Safety Practice Hires New Principal

Exponent welcomes Dr. Tim Morley to the firm

June 23, 2022

Exponent is pleased to announce Tim Morley, Ph.D., FRCPath, has joined Exponent's UK — Harrogate office as a principal scientist in the Chemical Regulation & Food Safety practice.

Dr. Morley brings more than 25 years of experience in the pharmaceutical industry to the firm. His background includes particular knowledge in small molecules, peptides, antibodies and natural products, and directing investigational new drug development from chemical hit to clinical candidate.

Dr. Morley also brings expertise in medical device safety with experience in product development, ISO-10993 biocompatibility, safety, and toxicological risk assessment.

"I am delighted that Tim has become part of the Exponent family," said Corporate Vice President, Director of UK Offices, and Practice Director Caroline Harris, Ph.D., CChem, FRSC. "His background and expertise in both medical devices and pharmaceuticals is a rare combination and our teams are delighted to have Tim's skill set available to support our clients with their technical and regulatory challenges."

Dr. Morley's past roles include senior and executive positions with pharmaceutical, biotechnology, medical device, medical technology, and rare disease companies. He is a board-certified toxicologist with additional expertise in drug metabolism and pharmacokinetics, clinical chemistry, pharmacology and bioanalysis, chemistry manufacturing controls, medical affairs, and pharmacovigilance. He is driven and focused on supporting clients across the total product life cycle, with the aim of delivering successful therapies and medical devices that meet patients' clinical needs. He is also a dedicated leader and enthusiastic about building and guiding teams aligned to strategic and organizational goals.

"I am excited to join Exponent, a company with such a wealth of expertise," Morley said. "I'm looking forward to making a contribution to supporting and resolving the challenges of the firm's pharmaceutical and medical device clients."